BioCentury
ARTICLE | Company News

Teva licenses pagoclone from Indevus

September 27, 2008 2:03 AM UTC

Indevus (NASDAQ:IDEV) granted Teva (NASDAQ:TEVA) an exclusive, worldwide license to pagoclone. The cyclopyrrolone GABA receptor agonist is in Phase II testing to treat stuttering with a Phase IIb trial expected to start in 1Q09. Teva will reimburse Indevus for the Phase IIb trial and conduct the Phase III program. If the Phase IIb trial is successful, the companies will share further development costs and profits, and Indevus will be eligible for up to $92.5 million in milestones and research expenses. ...